As per our research report, the size of the global antibodies market was valued at USD 130.9 Billion in 2020 and estimated to grow USD 223.7 Billion by the end of 2025. The market is growing at a CAGR of 11.31% during the forecast period.
Antibodies are proteins that are produced in response to specific antigens by plasma cells. They are also called immunoglobulin. These antibodies are used as diagnostics as well as Therapeutic purposes for several indications of diseases, including but not limited to, rheumatoid arthritis, non-Hodgkin lymphoma, psoriasis, Crohn’s disease, macular degeneration, hypercholesterolemia, and asthma. Owing to several product launches, the antibodies market is projected to witness steady growth. Effective harmonization of product development, approval, and registration guidelines in some of the major markets, such as the United States and European Union, can speed up the research and development of antibody-related products.
MARKET DRIVERS
A key factor driving the market growth during the forecast period is increasing demand for therapeutic antibodies, including monoclonal and polyclonal antibodies. Antibodies are also the dominant biopharmaceuticals targeting the abnormal cells specifically. Many pharmaceutical and biotechnology companies have therefore started to focus on developing advanced antibodies to treat chronic diseases like cancer, rheumatic heart disease, and arthritis.
In managing healthcare costs, high drug costs, particularly biologics, are becoming an increasingly important issue. With increasing spending on health care, the economic burden of cancer and other chronic diseases is growing. Improvements in the production of therapeutic antibodies have reduced the cost of manufacturing, and therefore, the penetration of antibodies has increased in cost-sensitive markets.
Another major factor driving the growth of the antibody market is the patent expiry of several successful monoclonal antibodies shortly. In a couple of years, most antibodies like Avastin, Herceptin, and Mabthera will lose their patents. For example, Herceptin's license (trastuzumab) expired in July 2014 in Europe and will expire in June 2019 in the United States. Many firms, including Amgen Inc., Synthon, Biocon, and Pfizer Inc., are developing trastuzumab biosimilar, which is expected to boost demand for products producing antibodies.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Analysed |
By Product Type, Indication, End User, Application and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This research report on the global antibodies market has been segmented based on the product type, indication, end-user, application, and region.
Antibodies Market - By Product Type:
Based on Product Type, Monoclonal antibodies segment accounts for the highest market share in the market.
Antibodies Market - By Indication:
Antibodies Market - By End User:
Based on End User, the Cancer indication type segment is predicted to account highest market share over the forecast period due to broad range applications of monoclonal antibodies for the treatment of various cancers.
Antibodies Market – By Application:
Based on Application, Hospitals are predicted to account for the highest share in the global antibodies market during the forecast period.
Antibodies Market – By Region:
In the last few years, North America was the market's largest revenue-generating area. Due to the presence of many other leading biopharmaceutical and biotechnology firms in this market, this region is expected to maintain its role during the forecast period.
TOP COMPANIES IN THE MARKET
Notable companies leading the global antibodies market profiled in the report are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and company, A.G. Scientific, Inc., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffmann-La Roche Ltd.
RECENT MARKET DEVELOPMENTS
In April 2016, the U.S. approved ERELZI-Novartis biosimilar to Enbrel. The European Union subsequently approved ERELZI in April 2017. Novartis opened the enormous market opportunity for RA in 28 EU member states with this authorization.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Monoclonal Antibodies
5.1.1.1 Murine
5.1.1.2 Chimeric
5.1.1.3 Humanized
5.1.1.4 Human
5.1.2 Polyclonal Antibodies
5.1.2.1 Type I
5.1.2.2 Type II
5.1.2.3 Type III
5.1.2.4 Type IV
5.1.2.5 Type V
5.1.2.6 Type VI
5.1.2.7 Type VII
5.1.2.8 Type VIII
5.1.3 Antibody-Drug Complexes
5.1.3.1 Immunogen Technology
5.1.3.2 Seattle Genetics Technology
5.1.3.3 Immunomedics Technology
5.2 By Indication
5.2.1 Cancer
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Abbott Diagnostics (U.S.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 A.G. Scientific, Inc. (U.S.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 AbbVie Inc. (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
